WuXi Biologics Begins Construction of Major Biologics Center in China
The new center will integrate biologics drug discovery, development, clinical manufacturing, and commercial manufacturing.
WuXi Biologics, a contract manufacturing and development organization (CDMO), has begun construction of a 1.6 million-ft2 global biologics innovation center in Fengxian, Shanghai in China that will integrate biologics discovery, development, clinical manufacturing, and commercial manufacturing, the CDMO announced in a Nov. 22, 2018 press release.
The new center will be cGMP-compliant and will house more than 3000 scientists as well as incorporate a modular and flexible design, the company has stated.
Commenting in a company press release, WuXi Biologics’ CEO Dr. Chris Chen said that the new center “will further expand WuXi Biologics’ unparalleled capacities.” “WuXi Biologics is committed to developing and manufacturing biologics more cost effectively as well as to providing a robust supply chain network for our global partners to benefit patients worldwide,” he stated in the release.
As of June 30, 2018, the company had a total of 187 integrated projects, including 98 projects in pre-clinical development stage; 78 projects in early-phase (Phase I and II) clinical development; 10 projects in late-phase (Phase III) development and one project in commercial manufacturing. The company estimates that its total biopharmaceutical production capacity in China, Ireland, Singapore, and the United States will reach 220,000 liters by 2021.
Source: WuXi Biologics
